CGRP: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here describes a protocol, and no outcome is promised. The aim is narrower: to show what the published literature on calcitonin gene-related peptide (CGRP) actually examined, in what models, and with what limits.

Module 1: What CGRP Is and How It Has Been Studied

CGRP is a 37-amino-acid neuropeptide. A 2023 review in Physiological Reviews described CGRP as a product of alternative splicing of the calcitonin gene, existing in α and β forms, and distributed widely across sensory neurons and the cardiovascular system (PMID 36454715). The same review positioned CGRP within the calcitonin peptide family alongside amylin, adrenomedullin and calcitonin, a family that shares overlapping receptor components (PMID 36454715).

A 2020 review in Expert Opinion on Therapeutic Targets summarised the peptide's discovery-to-drug arc, describing CGRP as released from trigeminal sensory nerve endings and as a central element of migraine pathophysiology research (PMID 32003253). Because of that arc, the CGRP literature is unusually layered: molecular pharmacology, rodent circuit neuroscience, human provocation studies and randomised clinical trials of antibodies and small-molecule antagonists all sit under the same keyword.

How the literature is organised

• Receptor pharmacology — component-level work on the CGRP receptor complex and its signalling, reviewed in a 2019 Handbook of Experimental Pharmacology chapter (PMID 30151722).
• Human provocation models — studies that infused CGRP in volunteers and patients, reviewed in a companion 2019 chapter (PMID 29896653).
• Circuit neuroscience — rodent work mapping CGRP-expressing neurons in the brainstem, thalamus and hippocampus (PMID 40632570).
• Therapeutic blockade — monoclonal antibodies and receptor antagonists designed to reduce CGRP signalling (PMID 36909005, PMID 23480465).

Limits of the evidence in Module 1. Definitions and family relationships are descriptive, not experimental. The reviews cited above summarised other laboratories' primary data, so terminology varies between papers, and the relative importance of α-CGRP versus β-CGRP in humans was not resolved by any single source cited here.

Module 2: Mechanism as Described in the Literature

The canonical CGRP receptor is described as a complex rather than a single protein. The 2019 signalling chapter reported that the receptor comprises calcitonin receptor-like receptor (CLR) paired with receptor activity-modifying protein 1 (RAMP1), and that downstream signalling has been characterised principally through Gs-coupled cAMP generation with additional pathways described (PMID 30151722). That chapter also noted receptor promiscuity across the calcitonin family, which complicates the interpretation of selectivity claims for antagonists (PMID 30151722).

At the tissue level, the 2023 Physiological Reviews synthesis described CGRP as one of the most potent endogenous vasodilators characterised, with actions on both smooth muscle and endothelium, and with roles extending beyond the trigeminovascular system into cardiovascular regulation (PMID 36454715). A 2019 chapter on cardiovascular risk framed the same vasodilatory biology as a protective reserve mechanism, which is why blockade raised cardiovascular questions in the first place (PMID 30879200).

In migraine specifically, the 2020 review described a model in which trigeminal activation releases CGRP, producing vasodilation and sensitisation of nociceptive pathways, with antibodies and antagonists intervening at ligand or receptor level (PMID 32003253). An older hypothesis paper proposed that some cardiovascular effects of nitroglycerin were mediated through CGRP release, an idea presented as a hypothesis rather than a demonstrated mechanism (PMID 12710904).

Limits of the evidence in Module 2. Receptor signalling data derive largely from transfected cell systems, and the cited chapter itself flagged translation from recombinant systems to native tissue as unsettled (PMID 30151722). The nitroglycerin proposal was explicitly a hypothesis paper (PMID 12710904).

Module 3: Reported Outcomes by Study

This module separates what was studied from what was concluded. No entry below should be read as an expected result in any individual.

Two patterns recur. First, most positive clinical findings concern blocking CGRP, not administering it; the human studies that administered CGRP did so to provoke headache as an experimental model (PMID 29896653). Second, the newer rodent work reassigned functions previously attributed to CGRP neurons, as when the 2025 preprint reported that ingestion-activated CGRP neurons governed learning rather than satiety (PMID 41278980).

Limits of the evidence in Module 3. Rodent circuit studies used genetically targeted manipulations that have no human equivalent, and the 2025 ingestion paper was a preprint that had not completed peer review at the time of posting (PMID 41278980). The oncology finding was in tumour models, not patients (PMID 42498203). Narrative reviews aggregate heterogeneous trials without pooled statistics (PMID 36909005).

Module 4: CGRP Side Effects: What Studies Report

Adverse events in this literature split into two categories that are frequently confused: effects reported when CGRP itself was administered experimentally, and effects reported when CGRP signalling was blocked therapeutically.

When CGRP was administered in human models

The 2019 review of human models reported that CGRP infusion produced headache in healthy volunteers and migraine-like attacks in people with migraine, alongside vasodilatory responses such as flushing (PMID 29896653). The 2023 physiology review similarly characterised CGRP as a potent vasodilator with corresponding haemodynamic consequences (PMID 36454715).

When CGRP signalling was blocked

The 2023 narrative review of monoclonal antibodies reported adverse events including injection-site reactions and constipation among the events described across the antibody trials it summarised (PMID 36909005). A 2019 chapter devoted specifically to cardiovascular risk discussed the theoretical concern that removing a potent vasodilatory reserve could matter in ischaemic settings, and reviewed the evidence available at that time (PMID 30879200). The 2023 physiology review also addressed long-term blockade as an open safety question given CGRP's distribution beyond the trigeminal system (PMID 36454715).

Behavioural signals in animals

The 2024 rodent study reported that CGRP drove anxiety-like behaviour via a defined molecular pathway in the dorsal hippocampus, a finding relevant to how CGRP signalling is interpreted beyond pain (PMID 38503899). The 2025 thalamic study linked CGRP neurons to the affective component of pain (PMID 40632570).

Limits of the evidence in Module 4. Adverse-event lists in narrative reviews are not incidence estimates, and the 2023 review did not present pooled safety statistics (PMID 36909005). Cardiovascular concerns were framed as mechanistic and unresolved rather than demonstrated harm (PMID 30879200). Rodent anxiety findings have no established human counterpart (PMID 38503899).

Module 5: Pharmacokinetics Where Data Exist

Quantitative human pharmacokinetic parameters for native CGRP are not detailed in the verified sources available for this course, and none are asserted here. What the literature does describe is qualitative and structural.

The 2023 physiology review described CGRP as a peptide released locally from nerve terminals and acting on nearby receptors, a spatial and temporal profile that distinguishes it from a systemically dosed drug (PMID 36454715). Human provocation studies used intravenous infusion precisely because a short-lived circulating peptide requires continuous delivery to sustain exposure, as summarised in the 2019 human-models chapter (PMID 29896653).

By contrast, the therapeutic agents that target CGRP were engineered around very different kinetics. The 2023 antibody review described monoclonal antibodies administered at monthly or quarterly intervals for migraine prevention, reflecting antibody half-lives far longer than that of the peptide itself (PMID 36909005). The 2009 discovery review described the difficulty of achieving adequate oral exposure with small-molecule receptor antagonists as a defining constraint on that programme (PMID 23480465).

Limits of the evidence in Module 5. No half-life, clearance or bioavailability value for CGRP is stated in this course because none appears in the verified sources; readers should treat any numeric PK figure encountered elsewhere as requiring its own primary citation. Antibody dosing intervals were described in review form rather than derived from a dedicated PK analysis here (PMID 36909005).

Module 6: Regulatory Status, Stated Factually

An important distinction: the regulatory landscape concerns drugs that target CGRP, not CGRP peptide itself.

• Approved products. The 2023 narrative review described monoclonal antibodies against CGRP or its receptor as an approved class for migraine prevention (PMID 36909005), and the 2020 review described small-molecule receptor antagonists developed for migraine as a parallel therapeutic route (PMID 32003253).
• Research-use-only material. Synthetic CGRP peptide supplied for laboratory work is generally labelled research use only and is not an approved drug product. Research-use-only material is not authorised for human administration, and the human data that exist came from controlled experimental infusion protocols in research settings (PMID 29896653).
• Compounding. Compounded preparations sit under a separate regulatory framework from approved drug products. Compounding rules govern what a licensed pharmacy may prepare and under what conditions; they do not constitute approval of a substance for a given indication.

This section is general regulatory information and is not legal advice; rules differ by jurisdiction and change over time.

Limits of the evidence in Module 6. Regulatory status is jurisdiction-specific and time-sensitive, and the reviews cited describe the therapeutic landscape as it stood at publication (PMID 36909005). No source cited here addresses the regulatory treatment of CGRP peptide sold outside approved channels.

What the Studies Did Not Test

Reading across all six modules, several gaps are explicit rather than inferred:

1. CGRP administration as a therapy. Human CGRP infusion studies were designed to provoke headache as a disease model, not to treat anything (PMID 29896653).
2. Long-term consequences of blockade. The 2023 physiology review and the 2019 cardiovascular chapter both framed extended CGRP blockade as an unresolved question rather than a settled one (PMID 36454715, PMID 30879200).
3. Human translation of circuit findings. The thalamic affective-pain pathway and the hippocampal anxiety pathway were characterised in rodents only (PMID 40632570, PMID 38503899).
4. Oncology application. The fremanezumab finding was reported in tumour models expressing CGRP, with no clinical endpoint tested (PMID 42498203).
5. Metabolic or appetite claims. The 2025 preprint reported that ingestion-activated CGRP neurons controlled learning but not satiety, which argues against extrapolating appetite claims from this circuit (PMID 41278980).
6. Nitroglycerin mechanism. The proposed CGRP mediation of nitroglycerin's cardiovascular effect was published as a hypothesis (PMID 12710904).

None of the studies summarised here evaluated CGRP peptide used outside a research or clinical setting, and none support any personal use decision. This page is for educational purposes only and is not medical advice; consult a licensed physician about any individual health question.

References

• CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond (Physiological Reviews, 2023)
• Ingestion-activated CGRP neurons control learning but not satiety (bioRxiv preprint, 2025)
• Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting (Expert Opinion on Therapeutic Targets, 2020)
• Thalamic CGRP neurons define a spinothalamic pathway for affective pain (PNAS, 2025)
• Understanding CGRP and Cardiovascular Risk (Handbook of Experimental Pharmacology, 2019)
• CGRP Receptor Signalling Pathways (Handbook of Experimental Pharmacology, 2019)
• CGRP in Human Models of Migraine (Handbook of Experimental Pharmacology, 2019)
• CGRP-mediated cardiovascular effect of nitroglycerin (Medical Hypotheses, 2003)
• Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review (Saudi Journal of Medicine & Medical Sciences, 2023)
• CGRP receptor antagonists: design and screening (Expert Opinion on Drug Discovery, 2009)
• Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab (European Journal of Pharmacology, 2026)
• CGRP causes anxiety via HP1γ-KLF11-MAOB pathway and dopamine in the dorsal hippocampus (Communications Biology, 2024)